Literature DB >> 11147600

Immunohistochemical expression of Ets-1 transcription factor and the urokinase-type plasminogen activator is correlated with the malignant and invasive potential in meningiomas.

G Kitange1, K Tsunoda, T Anda, S Nakamura, A Yasunaga, S Naito, S Shibata.   

Abstract

BACKGROUND: The Ets-1 transcription factor has been proposed to play an important role in the invasive process of tumor cells through the induction of urokinase-type plasminogen activator (u-PA).
METHODS: Because meningiomas are potentially invasive tumors, irrespective of their malignancy grades, the authors immunohistochemically investigated Ets-1 and u-PA expression in tissues obtained from 50 benign (16 meningotheliomatous, 14 fibrous, 13 transitional, 6 angiomatous, and 1 microcystic), 4 atypical, and 6 anaplastic meningiomas and correlated their results with the malignancy and invasive potential.
RESULTS: Ets-1 protein was expressed in 19 of the benign meningiomas (38%)whereas 31 (62%) were u-PA positive. The percentage of positive cells frequently was < 50%. In contrast, Ets-1 and u-PA expression was observed in all 4 atypical (100%) and all 6 anaplastic (100%) cases, respectively. The proportion of cells positive for Ets-1 and u-PA frequently were > or = 50%. A significant difference was observed between Ets-1 and u-PA expression in benign and high grade meningiomas (P < 0.0001). Moreover, Ets-1 expression was found to correlate significantly with u-PA positivity in meningiomas (P < 0.0001). Twenty-one of 60 meningioma cases (35%) showed infiltration either to the brain, dura mater, or bone. Eighteen of these 21 cases (85.7%) were positive for Ets-1 and u-PA. Ets-1 and u-PA positivity was found to correlate well with the invasive phenotype in meningiomas (P < 0.001).
CONCLUSIONS: The findings of the current study support the possibility that the Ets-1 transcription factor, through u-PA induction, may be involved in the invasive process in meningiomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11147600     DOI: 10.1002/1097-0142(20001201)89:11<2292::aid-cncr18>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

2.  Relationship between plasma D-dimer levels and clinicopathologic parameters in resectable colorectal cancer patients.

Authors:  Gang Xu; Ya-Li Zhang; Wen Huang
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

Review 3.  The biology of the Ets1 proto-oncogene.

Authors:  Jürgen Dittmer
Journal:  Mol Cancer       Date:  2003-08-20       Impact factor: 27.401

Review 4.  Molecular neuropathology of brain-invasive meningiomas.

Authors:  Niklas von Spreckelsen; Christoph Kesseler; Benjamin Brokinkel; Roland Goldbrunner; Arie Perry; Christian Mawrin
Journal:  Brain Pathol       Date:  2022-03       Impact factor: 6.508

5.  Overexpression of the Ets-1 transcription factor in human breast cancer.

Authors:  Y Buggy; T M Maguire; G McGreal; E McDermott; A D K Hill; N O'Higgins; M J Duffy
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

6.  Inhibiting cell migration and cell invasion by silencing the transcription factor ETS-1 in human bladder cancer.

Authors:  Li Liu; Yuchen Liu; Xintao Zhang; Mingwei Chen; Hanwei Wu; Muqi Lin; Yonghao Zhan; Chengle Zhuang; Junhao Lin; Jianfa Li; Wen Xu; Xing Fu; Qiaoxia Zhang; Xiaojuan Sun; Guoping Zhao; Weiren Huang
Journal:  Oncotarget       Date:  2016-05-03

7.  Ets-1 promoter-associated noncoding RNA regulates the NONO/ERG/Ets-1 axis to drive gastric cancer progression.

Authors:  Dan Li; Yajun Chen; Hong Mei; Wanju Jiao; Huajie Song; Lin Ye; Erhu Fang; Xiaojing Wang; Feng Yang; Kai Huang; Liduan Zheng; Qiangsong Tong
Journal:  Oncogene       Date:  2018-05-18       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.